Lunai Bioworks Inc. (LNAI) - 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 31, 2025, and the six months ended December 31, 2025. Lunai Bioworks Inc. (formerly Renovaro Inc.) is an AI-driven platform for precision medicine, diagnostics, and biodefense. The company operates through two primary segments: RENB (Renovaro Biosciences), focusing on allogeneic cell and gene therapies for oncology and infectious diseases, and BioSymetrics, an AI company integrating multimodal data for biomarker discovery. During the period, the company deconsolidated its subsidiary Gedi Cube B.V. following its bankruptcy declaration in September 2025.
Key Financial Metrics
| Metric | Six Months Ended Dec 31, 2025 | Six Months Ended Dec 31, 2024 |
|---|---|---|
| Revenue | $0 (Pre-revenue) | $0 (Pre-revenue) |
| Net Income (Loss) | $1,019,617 | $(51,464,429) |
| Operating Expenses | $5,131,774 | $57,884,869 |
| Cash and Cash Equivalents | $491,645 | $311,764 |
| Working Capital Deficit | $(19,487,088) | $(28,109,502) |
| Total Liabilities | $20,215,234 | $29,580,681 |
| Accumulated Deficit | $(509,442,953) | $(383,919,511) |
Debt and Liquidity: The company holds significant debt obligations, including convertible notes and promissory notes. As of December 31, 2025, current liabilities totaled $20,001,577, while current assets were only $514,489. The company reported a net cash outflow from operating activities of $2,420,323 for the six-month period, offset by $2,293,357 in cash provided by financing activities (including $750,000 from a private placement and $1.8M in notes payable).
Material Changes vs. Prior Period
- Net Income Turnaround: The company reported a net income of $1.02M for the six months ended Dec 31, 2025, compared to a net loss of $51.46M in the prior year. This reversal is primarily driven by non-operating items rather than core business profitability.
- Gain on Bankruptcy: A significant non-cash gain of $12,019,227 was recognized due to the deconsolidation of the bankrupt subsidiary Gedi Cube B.V.
- Debt Restructuring: The company recorded a $6,329,592 loss on extinguishment of debt following an exchange agreement where $9.7M in secured notes were swapped for $16.1M in convertible notes, which were immediately converted into 5.36 million shares of common stock.
- Expense Reduction: Operating expenses decreased by 91% year-over-year, largely due to the absence of a $47.6M goodwill impairment charge recorded in the prior year period.
- Asset Base: Total assets decreased from $8.23M to $6.67M, driven by the impairment of operating lease right-of-use assets and the sale of equity securities.
Guidance, Outlook, Risks, and Contingencies
Going Concern: The filing explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern. With a working capital deficit of nearly $19.5M and cash of only $491,645, the company is dependent on additional equity or debt financing to fund operations. Failure to secure funding could lead to a material reduction or suspension of operations.
Legal Proceedings: The company faces multiple significant legal contingencies:
- Securities Class Action: A settlement stipulation has been signed and is pending final court approval. Preliminary approval was granted in August 2025.
- Derivative Litigation: Multiple shareholder derivative actions (Koenig, Solak, Midler matters) are pending settlement approval.
- IP Disputes: The company is engaged in litigation against former partners (G Tech Bio, SRI) alleging fraud and falsification of study results, seeking recovery of approximately $25M. Conversely, these partners have filed cross-claims seeking termination of licenses.
- Investor Rights Dispute: Litigation with Weird Science LLC regarding registration rights remains active, with some claims dismissed and others pending.
Subsequent Events: On February 6, 2026, Nasdaq issued a delisting determination letter citing non-compliance with the minimum bid price requirement. The company has filed an appeal. Additionally, the liquidation of Grace Systems B.V. was registered in Amsterdam.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $491,645 cash balance against the $19.5M working capital deficit and ongoing burn rate.
- Financing Status: Confirm the status of the private placement agreement (Nov 2025) where only $750,000 of the $3.13M target was received as of period end.
- Legal Settlements: Monitor the final court approval status of the securities class action and derivative litigation settlements to determine potential cash outflows.
- Nasdaq Compliance: Track the outcome of the appeal regarding the Nasdaq delisting determination issued in February 2026.
- Debt Conversion: Review the terms of the remaining convertible notes and related party debt to assess dilution risks and maturity dates.